세계의 화학요법 유발성 말초신경병증 치료 시장 보고서(2025년)

Chemotherapy Induced Peripheral Neuropathy (CIPN) encompasses a range of symptoms and complications arising from specific chemotherapy drugs utilized in cancer treatment. It represents a form of peripheral neuropathy, involving impairment or dysfunction of the nerves connecting the brain and spinal cord to the body.

The primary drug categories for CIPN treatment include nerve protective therapy, anti-inflammatory therapy, neurotransmitter-based therapy, antioxidants, and others. Nerve protective therapy aims to preserve nerve health and function, crucial in managing chemotherapy-induced peripheral neuropathy for symptom relief. Treatment modalities encompass medications, therapies, and other interventions, with both branded and generic drugs available. These CIPN treatment drugs are distributed through hospital pharmacies, retail outlets, online platforms, and other channels, catering to end-users such as hospitals, research institutes, and specialty clinics.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The chemotherapy induced peripheral neuropathy treatment market research report is one of a series of new reports from The Business Research Company that provides chemotherapy induced peripheral neuropathy treatment market statistics, including the chemotherapy induced peripheral neuropathy treatment industry's global market size, regional shares, competitors with an chemotherapy induced peripheral neuropathy treatment market share, detailed chemotherapy induced peripheral neuropathy treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the chemotherapy induced peripheral neuropathy treatment industry. This chemotherapy induced peripheral neuropathy treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chemotherapy induced peripheral neuropathy treatment market size has grown strongly in recent years. It will grow from $1.66 billion in 2024 to $1.77 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to chemotherapy advancements, cancer treatment expansion, limited treatment options, increased cancer incidences, neurological research.

The chemotherapy induced peripheral neuropathy treatment market size is expected to see strong growth in the next few years. It will grow to $2.49 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to targeted therapies development, neuroprotective agents, integrated care pathways, patient-centered care models, regulatory support. Major trends in the forecast period include novel drug formulations, non-pharmacological interventions, neuroplasticity-based therapies, long-term survivorship support, cognitive behavioral therapies.

The forecast of 8.8% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. market by increasing the cost of neuroprotective agents and transcutaneous electrical nerve stimulation (TENS) devices sourced from Germany and Japan, thereby reducing pain management effectiveness and elevating oncology supportive care. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growth trajectory of the chemotherapy-induced peripheral neuropathy treatment market is anticipated to be driven by the increasing prevalence of cancer. Cancer, characterized by the unregulated proliferation and dissemination of abnormal cells within the body, often necessitates chemotherapy treatment. However, one of the potential side effects of certain chemotherapy drugs is chemotherapy-induced peripheral neuropathy (CIPN). The rising incidence of cancer cases globally is expected to contribute significantly to the expansion of the chemotherapy-induced peripheral neuropathy treatment market. For instance, a report by the American Cancer Society in January 2023 revealed an increase in newly diagnosed cases of liver cancer in females in the United States, rising from 12,660 cases in 2022 to 13,230 cases in 2023. This escalation in cancer cases acts as a catalyst propelling the growth of the chemotherapy-induced peripheral neuropathy treatment market.

The expansion of the chemotherapy-induced peripheral neuropathy treatment market is being driven by an increase in healthcare spending. Healthcare spending, which refers to the total financial resources allocated to the healthcare sector in a specific region or country, is essential for supporting treatments for chemotherapy-induced peripheral neuropathy (CIPN). This funding aims to alleviate and manage the adverse neurological effects caused by certain cancer therapies, ensuring the well-being of patients undergoing and recovering from chemotherapy. For example, in May 2023, a report from the Office for National Statistics, a UK government department, indicated that healthcare spending in the UK rose by 5.6% from 2022 to 2023, compared to a growth of 0.9% in 2022. The UK's healthcare expenditure was approximately $317.63 billion (£292 billion) in 2023. This increase in healthcare expenditure acts as a catalyst for the growth of the chemotherapy-induced peripheral neuropathy treatment market in the future.

Product innovation emerges as a prominent trend in the chemotherapy-induced peripheral neuropathy treatment market, with major market players prioritizing the development of novel products to enhance efficacy and consolidate their market position. Notably, in March 2023, AlgoTx, a clinical-stage company specializing in complex pain management, announced the FDA's approval of their Investigational New Drug Application (IND) for ATX01, a Phase 2 first-in-class candidate designed for individuals with erythromelalgia. The ATX01 for the Pain of Chemotherapy (ACT) study targeting chemotherapy-induced peripheral neuropathy (CIPN) has commenced randomized patient enrollment. Both programs have secured fast-track designation from the FDA, signifying their potential significance in addressing unmet medical needs.

Technological advancements, particularly the incorporation of quell technology, are a focal point for major companies in the chemotherapy-induced peripheral neuropathy treatment market as they endeavor to fortify their market standing. For instance, in January 2022, NeuroMetrix Inc., a US-based provider of non-invasive medical devices, attained breakthrough device designation from the U.S. Food and Drug Administration (FDA) for the mitigation of moderate to severe symptoms of chemotherapy-induced peripheral neuropathy (CIPN) persisting for at least 6 months post-chemotherapy completion. This designation marks a pivotal milestone for NeuroMetrix's efforts to introduce Quell technology to alleviate the distressing effects experienced by individuals grappling with CIPN.

In August 2024, Pharmacosmos Group, an international healthcare company based in Denmark, acquired G1 Therapeutics for $405 million. The purpose of this acquisition is to expand and accelerate the availability of COSELA(R) (trilaciclib), a treatment aimed at reducing chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (ES-SCLC). G1 Therapeutics is a US-based biopharmaceutical company that specializes in developing and commercializing small molecule therapeutics for cancer treatment.

Major companies operating in the chemotherapy induced peripheral neuropathy treatment market include Hoffmann-La Roche Ltd., Midatech Pharma PLC, Novartis AG, Lee's Pharmaceutical Holdings Limited, RELIEF THERAPEUTICS Holding SA, Eurofins Advinus, WEX Pharmaceuticals Inc., Asahi Kasei Corporation, MediciNova Inc., Solasia Pharma K.K., ESTEVE, ChromaDex Inc., Apollo Endosurgery Inc., REGENACY PHARMACEUTICALS INC., Novaremed AG, MAKScientific LLC, Sova Pharmaceuticals Inc., Kineta Inc., Aptinyx Inc., Apexian Pharmaceuticals Inc., WinSanTor Inc., Alexion Pharmaceuticals Inc., Sanofi, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Abbott Laboratories, Acorda Therapeutics Inc., Galena Biopharma Inc., Incyte Corporation

North America was the largest region in the chemotherapy induced peripheral neuropathy treatment market in 2024. Asia-Pacific and Europe are expected to be the fastest-growing regions in the forecast period. The regions covered in the chemotherapy induced peripheral neuropathy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chemotherapy induced peripheral neuropathy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chemotherapy induced peripheral neuropathy treatment market consists of sales of pharmaceutical drugs prescribed to alleviate chemotherapy-induced peripheral neuropathy symptoms. These drugs include pain relievers, antidepressants, anticonvulsants, and topical creams. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chemotherapy induced peripheral neuropathy treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chemotherapy induced peripheral neuropathy treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The chemotherapy induced peripheral neuropathy treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Nerve Protective Therapy; Anti-Inflammatory Therapy; Neurotransmitter Based Therapy; Antioxidant; Other Drug Classes
• 2) By Treatment: Medication; Therapy; Other Treatments
• 3) By Drug Type: Branded; Generic
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacies; Other Distribution Channels
• 5) By End-User: Hospitals; Research Institutes; Specialty Clinics
• Subsegments:
• 1) By Nerve Protective Therapy: Vitamin B Complex; Alpha-Lipoic Acid; Acetyl-L-Carnitine
• 2) By Anti-Inflammatory Therapy: Corticosteroids; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• 3) By Neurotransmitter Based Therapy: Gabapentin; Pregabalin; Duloxetine
• 4) By Antioxidant: N-acetylcysteine; Glutathione; Coenzyme Q10
• 5) By Other Drug Classes: Topical Treatments; Opioids; Herbal Remedies
• Companies Mentioned: Hoffmann-La Roche Ltd.; Midatech Pharma PLC; Novartis AG; Lee's Pharmaceutical Holdings Limited; RELIEF THERAPEUTICS Holding SA; Eurofins Advinus; WEX Pharmaceuticals Inc.; Asahi Kasei Corporation; MediciNova Inc.; Solasia Pharma K.K.; ESTEVE; ChromaDex Inc.; Apollo Endosurgery Inc.; REGENACY PHARMACEUTICALS INC.; Novaremed AG; MAKScientific LLC; Sova Pharmaceuticals Inc.; Kineta Inc.; Aptinyx Inc.; Apexian Pharmaceuticals Inc.; WinSanTor Inc.; Alexion Pharmaceuticals Inc.; Sanofi; Takeda Pharmaceutical Company Limited; Vertex Pharmaceuticals Incorporated; Abbott Laboratories; Acorda Therapeutics Inc.; Galena Biopharma Inc.; Incyte Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chemotherapy Induced Peripheral Neuropathy Treatment Market Characteristics

3. Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends And Strategies

4. Chemotherapy Induced Peripheral Neuropathy Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Chemotherapy Induced Peripheral Neuropathy Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Growth Rate Analysis
• 5.4. Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Total Addressable Market (TAM)

6. Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation

• 6.1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nerve Protective Therapy
• Anti-Inflammatory Therapy
• Neurotransmitter Based Therapy
• Antioxidant
• Other Drug Classes
• 6.2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Therapy
• Other Treatments
• 6.3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Branded
• Generic
• 6.4. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Other Distribution Channels
• 6.5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Research Institutes
• Specialty Clinics
• 6.6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Sub-Segmentation Of Nerve Protective Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vitamin B Complex
• Alpha-Lipoic Acid
• Acetyl-L-Carnitine
• 6.7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Sub-Segmentation Of Anti-Inflammatory Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• 6.8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Sub-Segmentation Of Neurotransmitter Based Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gabapentin
• Pregabalin
• Duloxetine
• 6.9. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Sub-Segmentation Of Antioxidant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• N-acetylcysteine
• Glutathione
• Coenzyme Q10
• 6.10. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Treatments
• Opioids
• Herbal Remedies

7. Chemotherapy Induced Peripheral Neuropathy Treatment Market Regional And Country Analysis

• 7.1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 8.1. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 9.1. China Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• 9.2. China Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 10.1. India Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 11.1. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• 11.2. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 12.1. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 13.1. Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 14.1. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• 14.2. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 15.1. Western Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• 15.2. Western Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 16.1. UK Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 17.1. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 18.1. France Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 19.1. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 20.1. Spain Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 21.1. Eastern Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• 21.2. Eastern Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 22.1. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 23.1. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• 23.2. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 24.1. USA Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• 24.2. USA Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 25.1. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• 25.2. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 26.1. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• 26.2. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 27.1. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 28.1. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• 28.2. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 29.1. Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• 29.2. Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Landscape And Company Profiles

• 30.1. Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Landscape
• 30.2. Chemotherapy Induced Peripheral Neuropathy Treatment Market Company Profiles
  • 30.2.1. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Midatech Pharma PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Lee's Pharmaceutical Holdings Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. RELIEF THERAPEUTICS Holding SA Overview, Products and Services, Strategy and Financial Analysis

31. Chemotherapy Induced Peripheral Neuropathy Treatment Market Other Major And Innovative Companies

• 31.1. Eurofins Advinus
• 31.2. WEX Pharmaceuticals Inc.
• 31.3. Asahi Kasei Corporation
• 31.4. MediciNova Inc.
• 31.5. Solasia Pharma K.K.
• 31.6. ESTEVE
• 31.7. ChromaDex Inc.
• 31.8. Apollo Endosurgery Inc.
• 31.9. REGENACY PHARMACEUTICALS INC.
• 31.10. Novaremed AG
• 31.11. MAKScientific LLC
• 31.12. Sova Pharmaceuticals Inc.
• 31.13. Kineta Inc.
• 31.14. Aptinyx Inc.
• 31.15. Apexian Pharmaceuticals Inc.

32. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chemotherapy Induced Peripheral Neuropathy Treatment Market

34. Recent Developments In The Chemotherapy Induced Peripheral Neuropathy Treatment Market

35. Chemotherapy Induced Peripheral Neuropathy Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer